Advancing Clinical Research in Metabolic Health and Weight Management

If you keep permanently off at least ten percent of your starting weight, you’re considered a successful loser. Successful long-term weight loss may be as much a function of personality and mental state as the choices you make about food and exercise. The characteristics commonly found in long-term losers are: Knowledge is power. Successful losers generally know the nutritional content of the foods they eat. They track calories, especially those from fat. They realize that certain foods are not worth the calories. Many evening snackers find that late-night pizza gives them a bellyache or the candy bar they devoured was all fat and no nutrition. You must find the right balance. People who successfully maintain weight loss exercise almost every day. Regular aerobic activity, such as walking or swimming, helps to burn off calories. To keep pounds off, you may have to do more than the 30 minutes a day that the American Heart Association recommends for good cardiovascular health. Weighing in regularly is an important reminder of what needs to be done.

For decades, weight management pharmacotherapy sat at the margins of mainstream medicine — underpowered agents, modest effect sizes, and a recurring pattern of post-approval safety signals that eroded clinical confidence. That picture has changed dramatically. The emergence of glucagon-like peptide-1 receptor agonists, and now dual GIP/GLP-1 co-agonists, has produced efficacy data the field has not seen before: mean weight reductions exceeding 15–20% of body weight in multi-year trials, with concordant improvements in cardiovascular and metabolic endpoints.

The SELECT trial — reporting a 20% reduction in major adverse cardiovascular events with weekly semaglutide 2.4 mg in patients with obesity but without diabetes — moved the conversation well beyond weight numbers. We are, arguably, witnessing the early phase of a genuine paradigm shift: pharmacological treatment of obesity as cardiovascular risk reduction, not merely body-composition management.

At AMRI, our research programme examines these agents not in isolation, but in the context of clinical practice realities. Who benefits most? What are the durability data off-treatment? How do older agents like orlistat, a pancreatic and gastric lipase inhibitor with over two decades of real-world use, compare in specific patient populations where injectables are contraindicated or unaffordable? These questions drive our review work.

The Institute also pays close attention to the safety dimension of this therapeutic category — both the biological safety profiles of individual agents, and the patient-safety challenge posed by the proliferation of unregulated online sources for prescription medications. Our drug-sourcing verification guides are developed in collaboration with FDA regulatory advisors to help clinicians and patients identify licensed dispensing channels and avoid the significant risks posed by counterfeit or sub-standard compounded formulations.